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In Vivo Dosimetry and Seed Localization in
Prostate Brachytherapy with Permanent
Implants
A.B. Rosenfeld, Senior Member, IEEE, D.L. Cutajar, M.L.F. Lerch, Member IEEE, G.J. Takacs,
J. Brady, T. Braddock, V. Pervertailo, Member, IEEE, J. Bucci, J. Kersley, M. Zaider and M. Zelefsky

Abstract—This paper reports on the development of an
interactive, intraoperative dose planning system for seed implant
brachytherapy in cancer treatment. This system involves in-vivo
dosimetry and the ability to determine implanted seed positions.
The first stage of this project is the development of a urethral
alarm probe to measure the dose along the urethra during a
prostate brachytherapy treatment procedure. Ultimately the
system will be used to advise the physicians upon reaching a
preset dose rate or dose after total seed decay in urethra during
the seed placement. The second stage is the development of a
method and instrumentation for in-vivo measurements of the
location of implanted seeds in the same frame as for dose
planning, and using these in intraoperative treatment planning.
We
have
developed
a
silicon
mini-detector
and
preamplifier/amplifier system to satisfy the spectroscopic
requirements of the urethral probe. This technique will avoid
complications related to overdosing the urethra and the rectum.

I. INTRODUCTION
transrectal ultrasound
REAL-TIME
placement of permanent interstitial

guided transperineal
I and 103Pd sources is
one of the treatment modalities available for early stage
prostate cancer. There has been a rapid expansion of the use of
this procedure, which is set to become the most common
treatment modality for early stage prostate cancer. Equivalent
biochemical control rates for low risk prostate cancer with
permanent seed implantation in comparison to radical
prostatectomy or external beam radiotherapy have been
confirmed [1,2]. These biochemical outcomes have been
favourable, but there has been little emphasis on the evaluation
and comparison of side effects and complications. Interstitial
125
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brachytherapy exhibits a different side effect profile than
radical prostatectomy or external beam radiotherapy.
Specifically, acute urinary side effects predominate in
interstitial prostate brachytherapy [3,4,5]. Urinary symptoms,
resulting in an increase of the International Prostate Symptom
Score (IPSS), are well-recognized side effects of interstitial
prostate brachytherapy, however more detailed evaluation of
these symptoms has been lacking. Wallner et al. [6] observed
an increase in grade-3 late urethral toxicity when the urethral
dose exceeded 400Gy. Recent recommendations by the
American Brachytherapy Society (ABS) for reporting
morbidity after prostate brachytherapy, request urethral doses
be recorded for correlation with urethral toxicity [7]. The ABS
recommends that doses be obtained at the centre of the urethra,
in half-centimeter intervals, from the base to the apex of the
prostate, reporting the maximum and mean obtained doses [7].
Medical complications associated with interstitial prostate
brachytherapy can result from errors in seed placement during
insertion. There are several factors that may lead to the
misplacement of seeds. The guiding needles may diverge
during insertion as different layers of tissue are penetrated [8],
resulting in the incorrect deposition of seeds, the seeds may
drift along the path of the needles, blood flow may alter the
seed positions, oedema may alter the size and shape of the
prostate, and gland motion may occur [9]. There is a need for
seed locations to be monitored in real-time during insertion
(intraoperatively). If a seed is misplaced, the required locations
of other seeds may be recalculated in compensation.
Intraoperative localization of inserted seeds will also provide a
method of online dosimetry. Many difficulties have been
encountered in the development of an inter-active planning
system in the operating theatre in prostate brachytherapy [10].
Current commercial systems use ultrasound visualization of
individual seeds or needles to predict the dose within the
prostate during treatment [11]. These systems are expensive,
have problems with artifacts as on 2D ultrasound seed imaging
and are unable to precisely determine individual seed
placement during a treatment procedure. The Memorial Sloan-
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Kettering Cancer Center (MSKCC) has developed an
intraoperative conformal optimization and planning system (I3D) for ultrasound-based transperineal prostate implants [12].
Optimal operation of this system requires accurate and
reproducible real-time position co-ordinates of each
successively implanted seed. The MSKCC has also recently
developed an intraoperative dosimetry system for prostate
brachytherapy based on the combination of two imaging
techniques [13]. Ultrasound images are obtained of the prostate
and lead markers. Fluoroscopic images of the implanted seeds
and lead markers are also obtained. The seed locations
obtained from the fluoroscopic images are superimposed onto
the prostate images using computer reconstruction. The entire
process takes approximately 10 minutes [13].
Here we propose the development of an alternative
intraoperative dosimetry system based on miniature solid-state
detectors used in spectroscopy mode. Brachytherapy seeds
contain radioactive sources, usually 125I or 103Pd. These
radioactive sources emit low energy photons with a distinct
energy spectrum, at very low dose rates that are hard to
measure with conventional detectors in confined spaces. The
ability of solid-state detectors to resolve these energies is
improving as new detector technologies are being developed.
At these low energies, approximately 27 keV for 125I, most
energy loss occurs through the photoelectric effect. The
Compton scattering cross-section is significant, but energy loss
due to the Compton effect is minimal. The attenuation
coefficient for low energy photons in tissue decreases with an
increase in energy. Spectral peaks of different energies will be
attenuated by different amounts as the emitted photons
penetrate the tissue. Using this principle, the ratio of peak
heights or area under the peaks in an obtained spectrum will
yield the distance from a measured seed to the detector. If the
distance to one detector is known, the triangulation of
distances from a non-coplanar array of detectors will yield the
seed position. Such a system will be intraoperative, and will
allow online dosimetry of the treatment.

TABLE I
6711 SEED PHOTON EMISSION [16]

Energy (keV)

Mean number/disintegration

35.492
31.877
30.980
27.472

0.0666
0.0438
0.201
0.756

27.202

0.405

Due to the presence of silver in the seed, silver fluorescent Xrays of energies 22.1keV and 25.2keV are also present [17].
Monte Carlo simulations were performed using EGSnrcV2
[18]. The FLURZnrc user code was used to simulate the 6711
seed in a liquid water phantom. The energy spectrum was
obtained at various locations for distances up to 5cm from the
seed centre at various angles around the seed. The area under
each photon peak was measured for each obtained spectrum.
The ratios of peak areas were calculated for the 27keV peak,
the 31keV peak and the 35keV peak. These obtained peak
ratios were plotted vs. distance from the seed and angle about
the seed axis. An algorithm relating peak ratio to seed location
was then constructed.
Given that we have a method for determining the distance
from a seed to a detector, if we have four or more non-coplanar
detectors, we can then determine the location of the seed. For
example, if we have 'n' detectors, each at a known location ri,
and the distance between a seed and each detector determined
from analysis of the spectrum is si, then we may determine the
seed location from minimization of the following function
n

{(r − r ) • (r − r ) − s }
i

i =1

i

2
i

(8)

The location r, which minimizes this, is then the estimate of
the seed location.

II. MATERIALS AND METHODS
Monte Carlo simulations and experimental measurements
were performed on an OncoSeed number 6711 from
Amersham Health [14]. This seed consists of radioactive 125I,
absorbed onto a silver rod, encapsulated in a hollow titanium
cylinder with welded ends. The geometry of the seed was
obtained from Williamson [15]. The silver rod is 3mm in
length and 0.5mm in diameter. A 1-micrometer thick coating
of silver halide is present on the rod. The radioactive iodine
was assumed to be at the midpoint of the silver halide coating.
The titanium shell was 4.5mm in length, 0.8mm in diameter,
was 0.06mm thick along the sides and 0.5mm thick at the end
welds. 125I decays via electron capture, emitting photons of
several distinct energies through gamma and X-ray emission.
Internal conversion and Auger electrons are also emitted, but
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were neglected, as they would not penetrate the titanium shell.
A 3.6keV photon was also neglected.

III. RESULTS
From Fig. 2 it can be seen that the photon peaks in the
energy spectrum of the 6711 seed are very sharp, with very
little scattering, even after the photons have traversed 5cm of
liquid water. This allows the use of spectroscopy for analyzing
the radiation throughout the prostate during interstitial
brachytherapy. The areas under the 27keV, 31keV and 35keV
peaks were measured for each obtained spectra and plots of
ratio vs. distance along the transverse axis of the seed were
obtained.
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from the seed to the point of measurement. The ratio of the
area under two peaks, a and b, may be given by

R a / b = R0a / b e − ∆µr

(2)

a/b

where R is the ratio of the area under peak a to the area
under peak b, R0a/b is the peak ratio at zero distance and ∆µ is
the difference in attenuation coefficients (µa-µb). Using (2) and
the data obtained from the FLURZnrc simulations of the 6711
seed in water, the following equations were devised.

R 27 / 35 = 14.41e −0.093r ± 3%
R 31/ 35 = 3.39e −0.036 r ± 4%

(3)

(4)
The distance to a 6711 seed within liquid water may be
calculated by measuring the ratio of the area underneath two
peaks in the spectrum and using (3) or (4). This assumes the
point of measurement is along the transverse axis of the seed.
Fig. 2. FLURZnrc energy spectrum of 6711 seed, measured 5cm from
seed along the transverse axis.

The previous calculations were repeated for spectra obtained
at different angles around a 6711 seed in a water phantom. A
plot of R27/35 vs. distance was obtained in Fig. 5.

Fig. 3. Ratio of the area under the 27keV peak to the area under the 35keV
peak vs. distance along the transverse axis for the 6711 seed, obtained from the
FLURZnrc spectra.

Fig. 5. The ratio of the area under the 27keV peak to the area under the
35keV peak vs. distance for a 6711 seed in a water phantom, calculated at
various angles around the seed. 90° represents measurements along the
transverse axis of the seed

Fig. 4. Ratio of the area under the 31keV peak to the area under the 35keV
peak vs. distance along the transverse axis for the 6711 seed, obtained from the
FLURZnrc spectra

Since scattering is minimal and the majority of energy loss
occurs through the photoelectric effect the area under each
peak as a function of distance may be given by

A = A0e − µr / r 2

(1)

where A is the area under a single peak, A0 is the area at zero
distance, µ is an effective attenuation coefficient of the
medium for photons of the peak energy and r is the distance

0-7803-8257-9/04/$20.00 © 2004 IEEE.

It can be seen that the peak ratios vary with changes in source
angle. This is due to the variation in thickness of the titanium
shell around the seed. Photons at lower angles traverse a
greater thickness of titanium, increasing the attenuation,
lowering the peak ratios. Simply finding the ratio of any two
peaks in a measured spectrum is not enough to determine the
distance to the seed. The peak ratios are a function of both
distance and angle. Assuming the distance from the source is
the order of centimeters the peak ratios may be represented as
separable functions of both distance and angle,

R = R0 f (r ) g (θ)

(5)

where f(r) is the distance dependent function of the peak ratio
and g(θ) is the angular dependent function of the peak ratio.
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f(r) was previously found to be e- ∆µr. To determine the angular
dependent function of the peak ratios, g(θ), the peak ratios vs.
angle were plotted for a fixed distance of 1cm, and normalized.

Fig. 6. Normalized plot of R27/35 vs. angle to determine the function
g(θ)27/35. Ratios were calculated 1cm from the seed centre.

downhill simplex method [19], and compared to the seed
location. The accuracy of this method for locating seeds is a
function of treatment volume, tetrahedron size, and the
assumed magnitude of uncertainties in seed-detector distances.
Table II gives results for trials of one million seed positions in
cubes of various edge lengths. These have been chosen to span
the range of treatment volumes, even though the shape differs
from a typical prostate.
The results of Table II show that the proportion of times
that a large seed location error occurs is sensitive to the
precision with which the seed-detector distances can be
determined. An increase in this by a factor of 2.5 results in an
increase by the same factor in the average error, but the
proportion of times an error of greater than 2.5mm occurs
increases by a much greater factor.
TABLE II
ERRORS IN SEED LOCATION

Cube
edge
length
(mm)
4.5
4.0
3.5
3.0
4.5
4.0
3.5
3.0

Fig. 7. Normalized plot of R31/35 vs. angle to determine the function
g(θ)31/35. Ratios were calculated 1cm from the seed centre.

After taking into account the angular variance in peak ratios,
(3) and (4) become

R 27 / 35 = 14.41e −0.093r g (θ) ± 5%
R

31 / 35

= 3.39e

−0.036 r

(6)

g (θ) ± 6%.

(7)
By calculating the area under the 27keV, 31keV and 35keV
peaks for an obtained spectrum, performing ratios of the
obtained areas and solving (6) and (7) simultaneously, the
distance to the seed as well as the angle of the seed to the point
of measurement may be determined.

Average
error
(mm)

3.0
3.0
2.5
2.5
2.5
2.5
2.5
2.5

1.8
1.6
1.4
1.2
0.72
0.63
0.56
0.49

Percentage
greater
than
2.5mm
18
12
7
3
0.12
0.011
0.0003
0.0012

Error (%)
in seeddetector
distance
5
5
5
5
2
2
2
2

Stage 1 in the development of an in vivo dosimetry and seed
localization system is the construction of the urethra alarm
probe. This uses spectroscopy to estimate the dose to the
urethra during interstitial brachytherapy treatment. The probe
consists of a silicon mini-detector of dimensions 0.8mm x
0.8mm x 3mm. This is connected to a preamplifier/amplifier
system by a thin 40cm cable, allowing the placement of the
detector within the prostate via a urinary catheter. The probe
was used to measure the spectrum of a 6711 seed in air at
25°C, while connected to the amplifier system via a 40cm
cable that would be used in practice.

In order to determine the practicality of this approach for
determining seed positions we have conducted simulations
where seeds are placed at random in a specified cubical
volume. Four detectors are placed in a tetrahedral
configuration. The distances between each detector and a given
seed are determined. These distances are then varied randomly
to simulate the effects of noise and uncertainties due to seed
anisotropy, etc. These uncertain distances are then used, along
with the known detector positions, in the equation (8) above.
The position r, which minimizes this, is determined by the

0-7803-8257-9/04/$20.00 © 2004 IEEE.

Tetrahedron
edge length
(mm)
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resolved. The 31keV and 35keV peaks are well resolved but do not contain
many counts. Also present is the 22keV silver X-ray peak. The 27keV peak is
outlined and has a FWHM of 2.3keV
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The 27keV peak is well resolved. Since scattering is minimal
and most energy loss is due to the photoelectric effect, the area
under the 27keV peak may be used to estimate the dose
received by the detector. The probe may be placed inside the
prostate during seed insertion to allow the physicians to ensure
the dose received by the urethra is within tolerable limits. The
photon spectrum of the 6711 seed was also measured with the
photons incident on the rear of the detector. There was no
apparent change in the measured spectrum, indicating that the
detector was fully depleted and has an isotropic response to
photon irradiation.

IV. CONCLUSION
The development of an intraoperative treatment planning
system for low dose rate brachytherapy of the prostate, based
on semiconductor detectors operating in spectroscopy mode,
seems to be feasible. Such a system will allow updating of the
treatment plan to correct for seed misplacement, and online
dosimetry. A method exists for locating seeds, based on
distances between four detectors and a seed, with each of these
distances being determined by observation of the ratio of
counts under different energy peaks. The determination of the
distance from a seed to a detector is possible theoretically but
has yet to be proven experimentally.

0-7803-8257-9/04/$20.00 © 2004 IEEE.

J.C. Blasko, P.D. Grimm, J.E.Sylvester et al, “Palladium-103
brachytherapy for prostate carcinoma”, Int J Radiat Oncol Biol Phys,
2000, vol 46, pp 839-850.
[2] H. Ragde, A. A. Elgamal, P.B. Snow et al, “Ten-year disease free
survival after transperineal sonography-guided iodine-125 brachytherapy
with or without 45-gray external beam irradiation in the treatment of
patients with clinically localized, low to high Gleason grade prostate
carcinoma”, Cancer, 1998, vol 83, pp 989-1001.
[3] D.Y. Gelblum, L. Potters, R. Ashley et al, “Urinary morbidity following
ultrasound-guided transperineal prostate seed implantation”, Int J Radiat
Oncol, Biol, Phys, 1999, vol 45, pp 59-67
[4] N. Lee, C. Wuu, R. Brody et al, “Factors predicting for postimplantation
urinary retention after permanent prostate brachytherapy”, Int J Radiat
Oncol Biol Phys, 2000, vol 481, pp 1457-1460.
[5] G.S. Merrick, W.M. Butler, J.H. Lief, and A.T. Dorsey, “Temporal
resolution of urinary morbidity following prostate brachytherapy”, Int J
Radiat Oncol, Biol Phys, 2000, vol 47, pp 121-128.
[6] K. Wallner, J. Roy and L. Harrison, “Dosimetry guidelines to minimize
urethral and rectal morbidity following transperineal I-125 prostate
brachytherapy”, Int J Radiat Oncol Biol Phys, 1995, vol 32, 465-471.
[7] S. Nag, R.J. Ellis, G.S. Merrick, R. Bahnson, K. Walner, R. Stock, “
American Brachytherapy Society (ABS) Recommendations for reporting
morbidity after prostate brachytherapy”, Int J Radiat Oncol Biol Phys,
2002, Vol.54, N2, pp.462-470.
[8] S. Nath, Z. Chen, N. Yue, S. Trumpore and R. Peschel, “Dosimetric
effects of needle divergence in prostate seed implant using 125-I and
103-Pd radioactive seeds”, Medical Physics 2000, vol 27, no 5, pp 10581066.
[9] R. Taschereau, J. Roy, J. Pouliot, “Monte Carlo simulations of prostate
implants to improve dosimetry and compare planning methods”, Medical
Physics, 1999, vol 26, no 9, pp 1952-1959.
[10] S. Nag, J.P. Ciezki, R. Cormack, S. Doggett, K. DeWyngaert, G.K.
Edmundson, R.G. Stock, N.N. Stone, Y. Yu, M.J. Zelefsky,
“Intraoperative planning and evaluation of permanent prostate
brachytherapy: report of the American Brachytherapy”, Int J Radiat
Oncol Biol Phys, 2001, Dec 1;vol 51(5), pp 1422-1430.
[11] “SPOT: 3D Ultrasound Brachytherapy Planning, System for Seed
Implants”, Nucletron brochure, 1999
[12] M.J. Zelefsky, Y. Yamada, G. Cohen, E.S. Venkatraman, A.Y. Fung, E.
Furhang, D. Silvern, M. Zaider, “Postimplantation dosimetric analysis of
permanent transperineal prostate implantation: improved dose
distributions with an intraoperative computer-optimized conformal
planning technique”, Int J Radiat Oncol Biol Phys ,2000, vol 48, pp 601608.
[13] D.A. Todor, M. Zaider, G.N. Cohen, M.F. Worman and M.J. Zelefsky,
“Intraoperative dynamic dosimetry for prostate implants”, Phys, Med,
Biol, 2003, vol 48, pp 1153-1171.
[14] Amersham Health Inc, 101 Carnegie Center, Princeton, NJ 08540-6231,
USA, Tel. +1 609 514 6000, Fax. +1 609 514 6660/6572.
[15] J.F. Williamson, “Monte Carlo evaluation of specific dose constants in
water for I-125 seeds”, Medical Physics, 1988, vol 15, no 5, pp 686-694.
[16] E. Browne, R.B. Firestone, “Table of radioactive isotopes”, edited by
V.S. Shirley, John Wiley and Sons, New York, 1986
[17] Schell et al, “Dose distributions of model 6702 I-125 seeds in water.” Int
J Radiat Oncol Biol Phys, 1997, vol 13, pp 795-799.
[18] I. Kawrakow and D.W.O. Rogers, The EGSnrc Code System, NRC
Report PIRS-701, (NRC, Ottawa, 2000).
[19] J.A. Nelder and R. Mead, Computer Journal, vol. 7, 1965, pp. 308-313

1598

